Background:Kaposi’s sarcoma (KS) is a potentially life-threatening multifocal neoplasm. Despite the significant decline in the incidence of acquired immune deficiency syndrome(AIDS)related KS with the use of highly a...Background:Kaposi’s sarcoma (KS) is a potentially life-threatening multifocal neoplasm. Despite the significant decline in the incidence of acquired immune deficiency syndrome(AIDS)related KS with the use of highly active antiretroviral therapy (HAART), some patients, even those with a good immune restoration, still have aggressive disease. Liposomal anthracyclines or combination chemotherapy are widely used but adverse effects limit their utilization. Objectives:We studied the efficacy and tolerance of docetaxel in the treatment of AIDS-related KS after pretreatment with anthracycline. Patients/methods and main outcome measure:A retrospective cohort study was done. Nine human immunodeficiency virus (HIV)-infected patients were treated from 1997 to 2002 with docetaxel. Tumour response was evaluated using the AIDS Clinical Trial Group (ACTG) staging criteria. Clinical and biological toxicity was evaluated. AIDS status with HIV viral load and CD4T-cell count were measured at the beginning and at the end of the treatment. Results:A major (complete or partial)response and a stabilization of the disease were demonstrated in seven and two patients, respectively. Grade 4 neutropenia and thrombocytopenia were observed in four of nine and one of nine patients, respectively. One patient died after sepsis. Conclusions:Docetaxel has a good and rapid efficacy in anthracycline-pretreated patients with severe AIDS-related KS. Phase II/III trials should be done to compare docetaxel with liposomal anthracyclines as a first-line treatment.展开更多
目的:观察乳腺癌术后不同化疗时机对患者免疫功能及生活质量的影响。方法:选取济宁市第一人民医院2017年1月至2019年1月行乳腺癌改良根治术后接受化疗的患者100例,采用随机数字表法分为对照组、早期组各50例,对照组术后4~6周开始化疗,...目的:观察乳腺癌术后不同化疗时机对患者免疫功能及生活质量的影响。方法:选取济宁市第一人民医院2017年1月至2019年1月行乳腺癌改良根治术后接受化疗的患者100例,采用随机数字表法分为对照组、早期组各50例,对照组术后4~6周开始化疗,早期组术后2周开始化疗,两组化疗方案一致。观察两组化疗前后CD4 +、CD8 +、CD4 +/CD8 +及血清免疫球蛋白A(IgA)、IgG水平,记录患者化疗不良反应及感染发生情况,评估两组末次随访时的生活质量。 结果:化疗前,两组CD_(4)^(+)、CD_(8)^(+)、CD_(4)^(+)/CD_(8)^(+)及血清IgA、lgG差异均无统计学意义(均 P > 0.05)。化疗后,早期组CD_(4)^(+)、CD_(4)^(+)/CD_(8)^(+)分别为(51.76±5.21)%、(2.00±0.25),高于对照组的(48.21±4.78)%、(1.70±0.21),CD_(8)^(+)为(25.93±2.43)%,低于对照组的(28.29±2.31)%,血清IgA、lgG分别为(3.24±0.38)g/L、(9.27±1.04)g/L,明显高于对照组的(2.75±0.37)g/L、(8.43±0.97)g/L,两组比较,差异均有统计学意义( t=3.55、4.98、6.50、6.53、4.18,均 P < 0.05)。化疗期间两组不良反应发生率差异均无统计学意义(均 P > 0.05),早期组感染发生率均显著低于对照组(均 P < 0.05)。末次随访时,早期组生活质量综合问卷(GQOLI-74)各项评分均显著高于对照组(均 P < 0.05)。 结论:早期化疗可显著减轻化疗对乳腺癌术后患者免疫功能的影响,降低感染发生率,提高患者生活质量。展开更多
文摘Background:Kaposi’s sarcoma (KS) is a potentially life-threatening multifocal neoplasm. Despite the significant decline in the incidence of acquired immune deficiency syndrome(AIDS)related KS with the use of highly active antiretroviral therapy (HAART), some patients, even those with a good immune restoration, still have aggressive disease. Liposomal anthracyclines or combination chemotherapy are widely used but adverse effects limit their utilization. Objectives:We studied the efficacy and tolerance of docetaxel in the treatment of AIDS-related KS after pretreatment with anthracycline. Patients/methods and main outcome measure:A retrospective cohort study was done. Nine human immunodeficiency virus (HIV)-infected patients were treated from 1997 to 2002 with docetaxel. Tumour response was evaluated using the AIDS Clinical Trial Group (ACTG) staging criteria. Clinical and biological toxicity was evaluated. AIDS status with HIV viral load and CD4T-cell count were measured at the beginning and at the end of the treatment. Results:A major (complete or partial)response and a stabilization of the disease were demonstrated in seven and two patients, respectively. Grade 4 neutropenia and thrombocytopenia were observed in four of nine and one of nine patients, respectively. One patient died after sepsis. Conclusions:Docetaxel has a good and rapid efficacy in anthracycline-pretreated patients with severe AIDS-related KS. Phase II/III trials should be done to compare docetaxel with liposomal anthracyclines as a first-line treatment.
文摘目的:观察乳腺癌术后不同化疗时机对患者免疫功能及生活质量的影响。方法:选取济宁市第一人民医院2017年1月至2019年1月行乳腺癌改良根治术后接受化疗的患者100例,采用随机数字表法分为对照组、早期组各50例,对照组术后4~6周开始化疗,早期组术后2周开始化疗,两组化疗方案一致。观察两组化疗前后CD4 +、CD8 +、CD4 +/CD8 +及血清免疫球蛋白A(IgA)、IgG水平,记录患者化疗不良反应及感染发生情况,评估两组末次随访时的生活质量。 结果:化疗前,两组CD_(4)^(+)、CD_(8)^(+)、CD_(4)^(+)/CD_(8)^(+)及血清IgA、lgG差异均无统计学意义(均 P > 0.05)。化疗后,早期组CD_(4)^(+)、CD_(4)^(+)/CD_(8)^(+)分别为(51.76±5.21)%、(2.00±0.25),高于对照组的(48.21±4.78)%、(1.70±0.21),CD_(8)^(+)为(25.93±2.43)%,低于对照组的(28.29±2.31)%,血清IgA、lgG分别为(3.24±0.38)g/L、(9.27±1.04)g/L,明显高于对照组的(2.75±0.37)g/L、(8.43±0.97)g/L,两组比较,差异均有统计学意义( t=3.55、4.98、6.50、6.53、4.18,均 P < 0.05)。化疗期间两组不良反应发生率差异均无统计学意义(均 P > 0.05),早期组感染发生率均显著低于对照组(均 P < 0.05)。末次随访时,早期组生活质量综合问卷(GQOLI-74)各项评分均显著高于对照组(均 P < 0.05)。 结论:早期化疗可显著减轻化疗对乳腺癌术后患者免疫功能的影响,降低感染发生率,提高患者生活质量。
